Schedule 13G ownership disclosure

Dyne Therapeutics Inc

Common Stock, par value $0.0001 · CUSIP: 26818M108

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • ForDyne B.V.

    Shares: 5,400,545 · Class: 4.8%

  • Forbion Capital Fund IV Cooperatief U.A.

    Shares: 4,036,476 · Class: 3.6%

  • Forbion IV Management B.V.

    Shares: 4,036,476 · Class: 3.6%

  • Forbion Growth Opportunities Fund II Cooperatief U.A.

    Shares: 1,426,370 · Class: 1.3%

  • Forbion Growth II Management B.V.

    Shares: 1,426,370 · Class: 1.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-072042
Form type
SCHEDULE 13G/A
Filer
Dyne Therapeutics, Inc.
CIK
CIK 1818794
Filed
May 15, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub